Appointment of M/s Panchal S K and Associates as the Statutory Auditor of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Asston Pharmaceuticals approved the appointment of M/s Panchal S K and Associates as the new Statutory Auditor on February 27, 2026, via a circulation resolution, on the recommendation of the Audit Committee. The appointment is to fill a 'casual vacancy' — meaning the previous auditor's position became vacant before the expiry of their term — and is subject to shareholder approval at the next general meeting. The incoming auditor firm (ICAI Firm Reg. No. 145989W, Peer Review No. 018089) was established in 2017 and is led by partner Swati Panchal, with experience spanning SMEs to large corporates. The intimation to BSE was made on March 2, 2026, with the company citing that board approval came after business hours on Friday February 27, followed by the weekend.
Routine regulatory disclosure for an auditor change. The casual vacancy language indicates the prior auditor departed mid-term, which investors may want to monitor for underlying reasons. Shareholder approval is still pending at the upcoming general meeting.